Cyrus Harmon - 20 Sep 2021 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
CHIEF TECHNOLOGY OFFICER, Director
Signature
/s/ John B. Moriarty, Jr., Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
20 Sep 2021
Transactions value $
-$315,600
Form type
4
Filing time
21 Sep 2021, 18:19:13 UTC
Previous filing
20 Aug 2021
Next filing
21 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Sale -$316K -12K -1.12% $26.30 1.06M 20 Sep 2021 Direct F1, F2
holding OLMA Common Stock 122K 20 Sep 2021 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F2 The weighted average sale price for the transaction reported was $26.30, and the range of prices were between $25.95 and $26.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.